Status:
COMPLETED
Paceport Swan-Ganz Data Collection Study
Lead Sponsor:
Montreal Heart Institute
Collaborating Sponsors:
Edwards Lifesciences
Conditions:
Right Ventricular Dysfunction
Right Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
RV dysfunction has been associated with increased mortality in the ICU and cardiac surgical patients. Thus, early identification of RV dysfunction at less severe stages will allow for earlier interven...
Detailed Description
The pulmonary artery catheter (PAC) consists of an intravenous device placed in the pulmonary artery to measure cardiac output, pulmonary artery pressures (Richard C, 2011) as well as cardiac filling ...
Eligibility Criteria
Inclusion
- Be ≥ 18 years of age
- Participate in the Informed Consent process and sign/date the approved informed consent forms
- Projected to receive Swan-Ganz catheter as part of procedure/standard of care with intermittent cardiac output and mixed venous oxygen saturation (SvO2) measures
Exclusion
- Refuse to sign consent
- Have left bundle branch block
- Have recurrent sepsis
- Have hypercoagulopathy
- Allergic to FORE-SIGHT Elite sensor adhesive
- Latex allergy due to presence of latex in the Swan-Ganz catheter balloon.
Key Trial Info
Start Date :
August 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT04782154
Start Date
August 9 2021
End Date
April 1 2022
Last Update
September 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montreal Heart Institute
Montreal, Quebec, Canada, H1T 1C8